Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981697 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3976199 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3976197 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3979905 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3981699 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3976204 | 1.00 | NTRK1 (0.48) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3979093 | 0.91 | NTRK1 (0.45) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3979094 | 0.91 | NTRK1 (0.45) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3979081 | 0.91 | NTRK1 (0.45) | NTRK1NTRK2GAASMN1; SMN2LMNA | |
| SCHEMBL3979086 | 0.91 | NTRK1 (0.45) | NTRK1NTRK2GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | claimed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | claimed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | claimed |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
| US-7538109-B2 | Quinoxalin-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-26 | — | — | US | disclosed |
| EP-1620409-B1 | QUINOXALIN-3-ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | NTRK1 2074/4885NTRK2 1488/4885GAA 3558/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | NTRK1 1224/4885NTRK2 928/4885GAA 1971/4885 |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | NTRK1 2053/4885NTRK2 1362/4885GAA 2736/4885 |
| US-20070027157-A1 | Quinoxalinone-3-one derivatives as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | NTRK1 986/4885NTRK2 545/4885GAA 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.